AR040036A1 - Tratamiento de la mucositis - Google Patents
Tratamiento de la mucositisInfo
- Publication number
- AR040036A1 AR040036A1 ARP030101748A ARP030101748A AR040036A1 AR 040036 A1 AR040036 A1 AR 040036A1 AR P030101748 A ARP030101748 A AR P030101748A AR P030101748 A ARP030101748 A AR P030101748A AR 040036 A1 AR040036 A1 AR 040036A1
- Authority
- AR
- Argentina
- Prior art keywords
- mucositis
- methods
- compositions
- nucleoside
- ribose
- Prior art date
Links
- 206010028116 Mucosal inflammation Diseases 0.000 title abstract 4
- 201000010927 Mucositis Diseases 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 abstract 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 abstract 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 abstract 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 abstract 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 abstract 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000001177 diphosphate Substances 0.000 abstract 1
- 235000011180 diphosphates Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940029575 guanosine Drugs 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000002324 mouth wash Substances 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 150000003214 pyranose derivatives Chemical class 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 1
- 229940045145 uridine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Composiciones y métodos para aliviar mucositis, donde dichos métodos y composiciones se refieren a la formulación o uso de determinados derivados de nucleósidos, en especial ADP-ribosa, que son de la fórmula general A-B-X y sales aceptables para uso farmacéutico de los mismos, donde "A" es una estructura nucleosídica seleccionada entre adenosina, guanosina y uridina; "B" es un enlace difosfato unido al carbono 5' de la porción ribosa del nucleósido; y "X" está unido a B que es una porción seleccionada entre hidrógeno, furanosa o piranosa. También se describen realizaciones de productos farmacéuticos y nutricionales líquidos de los mismos, incluyendo tabletas, enjuagues bucales u otras formas de productos que permitan recubrir eficazmente las áreas de mucosa oral, laríngea u otras áreas de mucosa. Se ha encontrado que estas composiciones y métodos alivian eficazmente la mucositis en individuos susceptibles, en especial cuando se administran antes, durante o después de los tratamientos asociados comúnmente con el desarrollo de mucositis, tal como determinadas quimioterapias, terapias de radiación o combinaciones de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38222502P | 2002-05-21 | 2002-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040036A1 true AR040036A1 (es) | 2005-03-09 |
Family
ID=29584378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101748A AR040036A1 (es) | 2002-05-21 | 2003-05-20 | Tratamiento de la mucositis |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20030236217A1 (es) |
| EP (1) | EP1509234B1 (es) |
| AR (1) | AR040036A1 (es) |
| AT (1) | ATE417616T1 (es) |
| AU (1) | AU2003230952A1 (es) |
| DE (1) | DE60325353D1 (es) |
| TW (1) | TW200402301A (es) |
| WO (1) | WO2003099297A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040989A1 (it) | 2004-05-18 | 2004-08-18 | Gentium Spa | Uso del sulglicotide per iul trattamento delle mucositi |
| US20050276762A1 (en) * | 2004-06-15 | 2005-12-15 | Tapas Das | Topical compositions containing 5'-adenosine-diphosphate ribose |
| GB0501476D0 (en) * | 2005-01-25 | 2005-03-02 | Heptagen Ltd | Treatment for mucositis |
| US20100190735A1 (en) * | 2006-03-28 | 2010-07-29 | Myrex Pharmaceuticals Inc. | Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis |
| US20070231274A1 (en) * | 2006-03-28 | 2007-10-04 | Myrex Pharmaceuticals Inc. | Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis |
| AR058834A1 (es) * | 2006-11-06 | 2008-02-27 | Univ Nac Quilmes | Un compuesto con actividad inhibitoria de una proteina celular rho-gtpasa, un procedimiento para su obtencion, composiciones farmaceuticas que lo comprenden y un metodo para el tratamiento de una indicacion mediada por una proteina celular rho-gtpasa |
| WO2009029692A1 (en) * | 2007-08-30 | 2009-03-05 | Prelief Inc. | Methods for improving healing of an oral lesion using a glycerophosphate salt |
| EP2203152A4 (en) | 2007-10-03 | 2011-05-25 | Myrex Pharmaceuticals Inc | MOUTH BATH AND METHOD OF USING SAME FOR TREATING A MUCITE OR STOMATITIS |
| CN102014919B (zh) | 2008-03-03 | 2015-02-25 | 托斯克公司 | 减少毒性的甲氨蝶呤佐剂及其使用方法 |
| PL2418945T3 (pl) * | 2009-04-15 | 2019-05-31 | Bmg Pharma S P A | Kompozycje soli mineralnej - kwasu sulfonowego i sposoby ich stosowania |
| WO2013089131A1 (ja) | 2011-12-16 | 2013-06-20 | 株式会社林原 | 歯周病の予防及び／又は治療のための口腔内洗浄用組成物 |
| WO2015116860A1 (en) | 2014-01-29 | 2015-08-06 | Vita Ice Therapeutics Llc | Edible oil compositions to treat oral complications and methods of using same |
| PL3416654T3 (pl) | 2016-02-18 | 2022-03-21 | Invirsa, Inc. | Medyczne zastosowanie adenozyno-5'-difosforanu rybozy (adpr) |
| EP4226971A1 (en) * | 2018-03-27 | 2023-08-16 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
| WO2020036982A1 (en) | 2018-08-14 | 2020-02-20 | Tosk, Inc. | Methods and compositions for treating mucositis |
| EP3836940A4 (en) | 2018-08-14 | 2022-05-18 | Tosk, Inc. | METHODS AND COMPOSITIONS FOR REDUCING FLUOROURACIL-INDUCED TOXICITY |
| EP3836942A4 (en) | 2018-08-14 | 2022-05-18 | Tosk, Inc. | METHODS AND COMPOSITIONS FOR REDUCING RADIATION-INDUCED TOXICITY |
| AU2019361999A1 (en) * | 2018-10-17 | 2021-02-25 | Lakewood Amedex, Inc. | Methods and compositions for treating oral mucositis |
| US11446303B2 (en) | 2019-06-21 | 2022-09-20 | Tosk, Inc. | Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions |
| CN116096422A (zh) | 2020-07-07 | 2023-05-09 | 托斯克公司 | 治疗或预防肺部疾病的尿苷磷酸化酶抑制剂 |
| KR102789553B1 (ko) | 2021-09-07 | 2025-04-03 | 주식회사 펄스인마이어스 | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4118672A (en) * | 1976-07-28 | 1978-10-03 | Nippon Electric Company, Ltd. | Attenuation equalizer having constant resistance |
| US5118672A (en) * | 1989-07-10 | 1992-06-02 | University Of Georgia Research Foundation | 5'-diphosphohexose nucleoside pharmaceutical compositions |
| US5817625A (en) * | 1992-09-21 | 1998-10-06 | Oncogene Science, Inc. | Methods of prevention of oral mucositis with transforming growth factor beta |
| JPH07247210A (ja) * | 1994-03-09 | 1995-09-26 | Sunstar Inc | 口腔用組成物 |
| US5656284A (en) * | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
| US5801159A (en) * | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| US5942243A (en) * | 1996-11-12 | 1999-08-24 | Polytherapeutics, Inc. | Mucoadhesive compositions for administration of biologically active agents to animal tissue |
| JP2001515916A (ja) * | 1997-09-11 | 2001-09-25 | オクシジェン，インコーポレイテッド | 悪性および伝染性疾患の治療用にニコチンアミド・アデニン・ジヌクレオチドならびにその類似物を用いる治療法 |
| US6197334B1 (en) * | 1998-04-13 | 2001-03-06 | Donald V. Renda | Lozenge and method of making |
| US6624150B2 (en) * | 1999-02-26 | 2003-09-23 | Inspire Pharmaceuticals, Inc. | Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| US6528042B1 (en) * | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| CA2433840C (en) * | 2001-01-04 | 2010-05-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof |
-
2003
- 2003-04-18 WO PCT/US2003/011840 patent/WO2003099297A1/en not_active Ceased
- 2003-04-18 DE DE60325353T patent/DE60325353D1/de not_active Expired - Lifetime
- 2003-04-18 AT AT03724064T patent/ATE417616T1/de not_active IP Right Cessation
- 2003-04-18 US US10/419,007 patent/US20030236217A1/en not_active Abandoned
- 2003-04-18 AU AU2003230952A patent/AU2003230952A1/en not_active Abandoned
- 2003-04-18 EP EP03724064A patent/EP1509234B1/en not_active Expired - Lifetime
- 2003-05-02 TW TW092112205A patent/TW200402301A/zh unknown
- 2003-05-20 AR ARP030101748A patent/AR040036A1/es unknown
-
2005
- 2005-12-27 US US11/318,677 patent/US20060105985A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/931,613 patent/US20080081796A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060105985A1 (en) | 2006-05-18 |
| HK1074784A1 (en) | 2005-11-25 |
| US20080081796A1 (en) | 2008-04-03 |
| DE60325353D1 (de) | 2009-01-29 |
| ATE417616T1 (de) | 2009-01-15 |
| AU2003230952A1 (en) | 2003-12-12 |
| EP1509234B1 (en) | 2008-12-17 |
| TW200402301A (en) | 2004-02-16 |
| WO2003099297A1 (en) | 2003-12-04 |
| EP1509234A1 (en) | 2005-03-02 |
| US20030236217A1 (en) | 2003-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040036A1 (es) | Tratamiento de la mucositis | |
| UY27875A1 (es) | Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae | |
| PA8559501A1 (es) | Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno | |
| GT199900203A (es) | Composiciones de celecoxib. | |
| BRPI0412489A (pt) | composição de confeito mastigável liberando para as superfìcies dentárias uma dose unitária de uma enzima | |
| AR035642A1 (es) | Uso de una composicion de celecoxib para el alivio rapido del dolor | |
| ES2146300T3 (es) | Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos. | |
| AR037407A1 (es) | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii | |
| GT200000005A (es) | Derivados biciclicos sustituidos utiles como agentes contra el cancer. | |
| ES2063033T3 (es) | Empleo de igf-ii en el tratamiento de la enfermedades de los huesos. | |
| CL2004000931A1 (es) | Pelicula consumible adaptada para adherirse y disolverse en la cavidad bucal que comprende un almidon modificado y un agente farmaceuticamente activo. | |
| AR052057A1 (es) | Composiciones orales que contienen extractos de rosmarinus y metodos ralacionados | |
| CR7716A (es) | Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor | |
| ES2194935T3 (es) | Preparados estables de transglutaminasa y procedimiento para su preparacion. | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| PA8581801A1 (es) | Formulaciones que contienen un compuesto de indolinona | |
| BRPI0311189B8 (pt) | composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso | |
| UY28356A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos | |
| AR021086A1 (es) | Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento. | |
| AR022250A1 (es) | Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b. | |
| AR066666A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| ES2526359T3 (es) | Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos | |
| GT199900083A (es) | Combinaciones terapeuticas para la fragilidad musculoesqueletica. | |
| GT200600397A (es) | Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales | |
| BR0206087A (pt) | Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |